Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction

Clinical Kidney Journal

Volumn 6, Issue 3, 2013, Pages 287-294

  Zitt, Emanuel ^a   Fouque, Denis ^b   Jacobson, Stefan H ^c   Malberti, Fabio ^d   Ryba, Miroslav ^e   Ureña, Pablo ^f   Rix, Marianne ^g   Dehmel, Bastian ^h   Manamley, Nick ⁱ   Vervloet, Marc ^j  

^a Hospital Saint John of God   (Austria)

^b UNIVERSITÉ DE LYON   (France)

^c DANDERYD HOSPITAL   (Sweden)

^d CREMONA HOSPITAL   (Italy)

^e Krajska Nemocnice Liberec   (Czech Republic)

^f Clinique du Landy   (France)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h AMGEN INC   (United States)

ⁱ AMGEN LTD   (United Kingdom)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

chronic kidney disease; cinacalcet; secondary hyperparathyroidism; serum phosphorus

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D;

ADULT; ARTICLE; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT DURATION; TREATMENT REFUSAL;

EID: 84878541059     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft026     Document Type: Article

References (38)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999; 73: S14-S19
3. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
5. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
6. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
7. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
8. Giachelli CM. The emerging role of phosphate in vascular calcification. J Kidney Int 2009; 75: 890-897
9. Hruska KA, Saab G, Mathew S et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-315
10. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
11. Kanbay M, Goldsmith D, Akcay A et al. Phosphate-the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 2009; 27: 220-230
12. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523
13. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
14. Danese MD, Belozeroff V, Smirnakis K et al. Consistent control of mineral and bone disorder in incident hemodialy-sis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76 (Suppl. 113): S1-S130
16. Uribarri J. Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1290-1292
17. Drake TG, Albright F, Castleman B. Parathyroid hyperplasia in rabbits produced by parenteral phosphate administration. J Clin Invest 1937; 16: 203-206
18. Raisz LG. Bone resorption in tissue culture. factors influencing the response to parathyroid hormone. J Clin Invest 1965; 44: 103-116
19. Hruska KA, Mathew S, Lund R et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157
20. Moe SM, Drueke TB. Management of secondary hyperpar-athyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23: 369-379
21. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-4045
22. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemo-dialysis. N Engl J Med 2004; 350: 1516-1525
23. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
24. Urena P, Jacobson SH, Zitt E et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical prac-tice-the ECHO observational study. Nephrol Dial Transplant 2009; 24: 2852-2859
25. Martin KJ, Juppner H, Sherrard DJ et al. First-and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005; 68: 1236-1243
26. Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45
27. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947
28. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemo-dialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
29. Kilpatrick RD, Gill KS, Block GA. [SA-PO2403] Exploring the Relationship between Temporal Trends in PTH, P and Ca in HD Patients. Abstract presented at the American Society of Nephrology Annual Meeting Denver, CO, 16-21 November 2010
30. Shigematsu T, Akizawa T, Uchida E et al. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 2009; 29: 230-236
31. Malberti F, Marcelli D, Conte F et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12:1242-1248
32. Kestenbaum B, Andress DL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016
33. Chertow GM, Johansen KL, Lew N et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57: 1176-1181
34. Kaysen GA. Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? Kidney Int Suppl 2003:S92-S98
35. Vervloet M, Bencova V, Malberti F et al. 'Real-World' use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study. Clin Nephrol 2010; 74:198-208
36. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51: 987-995
37. Ates F, Koken T, Demir S et al. Comparison of three different immunoassay methods for the evaluation of intact parathyroid hormone levels in hemodialysis patients. ScandJ Clin Lab Invest 2011; 71: 227-231
38. Souberbielle J-CP, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2009; 77: 93-100